Related Experiment Video
Updated: Jul 30, 2025

SUMO-Binding Entities SUBEs as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
A new immuno-oncology target - SUMOylation
1Division of Surgical Sciences, Department of Surgery, UC San Diego Health, La Jolla, CA 92037, USA; Moores Cancer Center, UC San Diego Health, La Jolla, CA 92037, USA.
Protein modification by small ubiquitin-like modifiers (SUMO) offers a novel strategy to activate antitumor immunity, addressing limitations in current cancer immunotherapy responses.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immunotherapy has revolutionized cancer treatment, leading to durable patient responses.
- However, a significant number of cancers remain unresponsive to existing immunotherapies.
- Novel therapeutic targets are essential to overcome current treatment limitations.
Purpose of the Study:
- To explore the role of protein modification by small ubiquitin-like modifiers (SUMO) in activating antitumor immunity.
- To investigate SUMOylation as a potential novel target for cancer immunotherapy.
Main Methods:
- Analysis of emerging data on SUMOylation.
- Investigation of mechanisms linking SUMOylation to immune activation.
Main Results:
- Emerging data indicate that SUMOylation is a viable mechanism for activating antitumor immunity.
- SUMOylation presents a novel target for enhancing cancer immunotherapy efficacy.
Conclusions:
- Protein modification via SUMOylation represents a promising new avenue for cancer treatment.
- Targeting SUMOylation could improve responses to immunotherapy in non-responsive cancers.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Abnormal Proliferation
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
PI3K/mTOR/AKT Signaling Pathway
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

